Exelixis (EXEL) Tops Q1 EPS by 6c

Exelixis (NASDAQ: EXEL) reported Q1 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $8.08 million.

Cash and cash equivalents, short- and long-term investments and short- and long-term restricted cash and investments totaled $197.6 million at March 31, 2015, compared to $242.8 million at December 31, 2014.

For earnings history and earnings-related data on Exelixis (EXEL) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• GNI Group acquires Ayumi Pharmaceutical for ¥44.8 billion
• NHC acquires 35 facilities from NHI for $560 million